Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

European Journal of Cancer Care
A BertautP Arveux

Abstract

We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not receive trastuzumab was similar to that in women with triple-negative tumours. A higher relative excess risk of death by cancer was observed for high-grade tumours [RER, relative excess rates = 1.76 (95% CI, confidence intervals: 1.17-2.62) for Scarff Bloom Richardson grade 3 vs. 1 + 2], while a lower risk was observed for luminal tumours [RER = 0.49 (95% CI: 0.27-0.89)] and HER2-positive tumours treated with trastuzumab [RER = 0.28 (95% CI: 0.14-0.59)], both compared with triple-negative tumours. Surgery of the primary tumour was associated with better survival [RE...Continue Reading

References

Nov 7, 1991·The New England Journal of Medicine·L Norton
Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
Jun 8, 2001·International Journal of Cancer. Journal International Du Cancer·K S ChiaH P Lee
Jan 5, 2002·Breast Cancer Research and Treatment·P GrosclaudeM Sauvage-Machelard
Jan 24, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MosconiM Maltoni
Feb 1, 2003·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A R CarmichaelJ M Dixon
Dec 26, 2003·Statistics in Medicine·Paul W DickmanTimo Hakulinen
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice AndreMarc Spielmann
May 17, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elisabetta RapitiChristine Bouchardy
Oct 27, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T S DabakuyoP Arveux
Jul 22, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R LargillierE Chamorey
Aug 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaheenah DawoodSharon H Giordano
Oct 22, 2008·Breast Cancer Research and Treatment·C CluzeN Bossard
Dec 11, 2008·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Jul 18, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BeslijaUNKNOWN Central European Cooperative Oncology Group (CECOG)
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaheenah DawoodSharon H Giordano
Apr 30, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DawoodS H Giordano
Jun 22, 2011·Biometrics·Maja Pohar PermeJacques Estève
Nov 15, 2011·Methods in Molecular Biology·Stacy M Cowherd
May 4, 2012·Journal of Pharmacy Practice·Carrie L Griffiths, Jacqueline L Olin
Jun 22, 2012·Frontiers in Oncology·Thuy Vu, Francois X Claret
Jul 21, 2012·International Journal of Cancer. Journal International Du Cancer·Claudia AllemaniMichel P Coleman
Oct 17, 2012·International Journal of Women's Health·Olivier BrouckaertPatrick Neven
Oct 10, 2013·Breast Cancer Research and Treatment·Dorien J A LobbezooVivianne C G Tjan-Heijnen
Nov 13, 2013·The Breast : Official Journal of the European Society of Mastology·Uwe GüthMarcus Vetter

❮ Previous
Next ❯

Citations

Jun 16, 2017·Archives of Gynecology and Obstetrics·Karin KastPauline Wimberger
Aug 6, 2021·JCO Clinical Cancer Informatics·Carlos H BarcenasGabriel N Hortobagyi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.